Loading...
Mesa Laboratories Inc (MLAB) is not a strong buy for a beginner, long-term investor at this moment. While the technical indicators show some bullish signs, the lack of significant trading trends, weak financial performance in the latest quarter, and absence of positive news or catalysts suggest a cautious approach. The stock may not align well with the user's investment scenario.
The MACD histogram is positive at 0.346, indicating a bullish trend, but it is contracting. RSI is at 69.785, which is neutral. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near resistance levels (R1: 96.065), suggesting limited upside potential in the short term.
Analysts have raised the price target twice recently, citing strong Q3 revenue and margin expansion. Bullish moving averages indicate a positive technical setup.
Net income and EPS have dropped significantly YoY in the latest quarter. No recent news, significant trading trends, or congress trading data to support a strong buy case. The stock is trading near resistance levels, limiting immediate upside potential.
In 2026/Q3, revenue increased by 3.64% YoY to $65.13M. However, net income dropped by -316.59% YoY to $3.63M, and EPS fell by -309.68% YoY to 0.65. Gross margin improved slightly to 64.18%, up 1.45% YoY.
Wells Fargo raised the price target twice, from $75 to $83 in December 2025 and from $83 to $94 in February 2026, maintaining an Equal Weight rating. Analysts note strong Q3 performance and shareholder-friendly steps but remain cautious with an Equal Weight stance.